Antiparkinsonian Drugs and Motor Complications
On this page
Direct answer
Antiparkinsonian drugs replace or mimic striatal dopamine, and levodopa with carbidopa remains the most effective agent for motor symptoms. Long-term levodopa produces motor complications, namely wearing-off, on-off fluctuations and dyskinesias. These are managed by adjusting dose timing, adding COMT or MAO-B inhibitors or dopamine agonists, and referring for device-aided therapy when oral options fail.
What you must remember
- Levodopa with carbidopa: the gold standard; carbidopa blocks peripheral conversion to dopamine, which reduces nausea and increases central delivery.
- Dopamine agonists: pramipexole, ropinirole and rotigotine cause somnolence, oedema and impulse control disorders; ergot agonists are avoided because of fibrotic complications.
- COMT inhibitors: entacapone and opicapone prolong the action of each levodopa dose; tolcapone carries a risk of hepatotoxicity and needs liver monitoring.
- MAO-B inhibitors: selegiline and rasagiline reduce off-time; avoid combining them with pethidine, tramadol or SSRIs because of serotonin toxicity.
- Amantadine: an NMDA antagonist that treats levodopa-induced dyskinesias and offers modest symptomatic benefit.
- Wearing-off: each dose lasts a shorter time, producing end-of-dose akinesia; smaller, more frequent doses are the first step.
- Dyskinesias: peak-dose chorea and dystonia; lower the peak dose or add amantadine rather than pushing levodopa higher.
- Withdrawal and blockers: abrupt cessation of dopaminergic therapy can cause parkinsonism-hyperpyrexia syndrome, and dopamine antagonists such as metoclopramide and haloperidol worsen parkinsonism.
A stepwise escalation for motor fluctuations
Motor complications are managed in layers, moving to continuous delivery only when oral measures fail. Each step should be assessed against a patient diary before the next is added.
- Review the diary: map on and off periods across the day, because peak-dose dyskinesia and wearing-off need opposite dose changes.
- Adjust levodopa timing: give smaller, more frequent doses, ideally about 30 minutes before meals, since dietary protein competes for absorption.
- Add a COMT inhibitor: entacapone extends each levodopa dose and shortens off-time, with a levodopa dose adjustment often needed.
- Add a dopamine agonist: pramipexole or ropinirole covers off episodes, starting low and warning about sleep attacks and impulse control.
- Treat dyskinesias separately: reduce the peak levodopa dose or add amantadine, balancing the change against the risk of new off periods.
- Consider continuous delivery: apomorphine infusion or levodopa-carbidopa intestinal gel through a jejunal tube suits refractory fluctuations.
- Refer for deep brain stimulation: subthalamic nucleus or globus pallidus internus stimulation suits levodopa-responsive patients with disabling fluctuations, after cognitive and psychiatric screening.
Where the exam tries to catch you
Antiparkinsonian stems usually test an interaction or the wrong fix for a given complication.
- Trap: using metoclopramide or haloperidol for nausea in a parkinsonian patient Correct: central dopamine blockers worsen parkinsonism, so choose a non-dopaminergic antiemetic.
- Trap: giving pethidine or tramadol for pain to a patient on MAO-B inhibitors Correct: the combination risks serotonin toxicity, so pick an alternative analgesic.
- Trap: increasing levodopa to treat peak-dose dyskinesia Correct: lowering the peak dose, with amantadine as an adjunct, controls dyskinesia better.
- Trap: choosing an ergot agonist such as bromocriptine for a long-standing patient Correct: non-ergot agonists are preferred because ergots cause valvular and pleuropulmonary fibrosis.
Frequently asked questions
Which drug is the most effective for motor symptoms of Parkinson disease?
Levodopa combined with carbidopa is the most effective drug for motor symptoms of Parkinson disease. Carbidopa blocks peripheral decarboxylation, so more levodopa reaches the brain and nausea is reduced.
Why are ergot-derived dopamine agonists avoided in Parkinson disease?
Ergot-derived dopamine agonists such as bromocriptine, cabergoline and pergolide are linked to fibrotic complications, including valvular heart disease and pleuropulmonary fibrosis. Non-ergot agonists such as pramipexole and ropinirole are preferred instead.
Which drugs interact dangerously with selegiline?
Selegiline and rasagiline should not be combined with pethidine, tramadol or SSRIs, because of the risk of serotonin syndrome. Non-selective MAO inhibitors are also contraindicated with levodopa, as they can cause hypertensive reactions.
How is peak-dose dyskinesia treated in Parkinson disease?
Peak-dose dyskinesia is treated by lowering the peak levodopa dose, spreading doses more evenly, or adding amantadine, which has antidyskinetic effects. Continuous delivery or deep brain stimulation is considered when oral options fail.
Which motor complication responds to deep brain stimulation?
Deep brain stimulation of the subthalamic nucleus or globus pallidus internus treats disabling motor fluctuations and dyskinesias in patients who respond well to levodopa. Candidates need cognitive, psychiatric and surgical screening before selection.